Back to top
more

Lineage Cell Therapeutics (LCTX)

(Delayed Data from AMEX)

$1.01 USD

1.01
1,166,777

0.00 (0.00%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $1.00 -0.01 (-0.99%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (141 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Lineage Cell (LCTX) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of +50.00% and +75.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Brookdale Senior Living (BKD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Brookdale (BKD) delivered earnings and revenue surprises of -28.57% and -0.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 31.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Editas (EDIT) delivered earnings and revenue surprises of 15.69% and 385.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 75% and 160.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 50% and 222.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

MeiraGTx (MGTX) delivered earnings and revenue surprises of -14.89% and 4,264%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

What Makes Lineage Cell (LCTX) a New Buy Stock

by Zacks Equity Research

Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 25% and 10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Beam Therapeutics (BEAM) delivered earnings and revenue surprises of 1.77% and 16.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study

by Zacks Equity Research

Lineage (LCTX) rises 10% on positive imaging analyses results from the phase I/IIa study of OpRegen in patients with geographic atrophy secondary to age-related macular degeneration.

Zacks Equity Research

Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 25% and 21.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 8.06% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 2.70% and 1.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 21.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 35.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 3.17% and 8.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?